Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

SYDNEY, AU, Nov 11, 2022 – (ACN Newswire) – Novotech, the leading Asia Pacific biotech specialist CRO, is sponsoring BioCentury-BayHelix East-West Summit 2022, and Novotech's Chief Commercial Officer Barry Murphy is Session Chair for the expert panel on How to Build and Finance an East-West MRCT Strategy Workshop at the Summit (14-16 November 2022).

Novotech is sponsoring the Networking Reception and Dinner.

Workshop details:
Global Development Workshop: How to Build and Finance an East-West MRCT Strategy
November 15, 2022
2:30 PM – (PACIFIC TIME ZONE)
BioCentury-BayHelix East-West Summit 2022
https://conferences.biocentury.com/china-healthcare-summit/schedule

Panelists are:
– PATRICIA KEEGAN, M.D.: Chief Medical Officer, Junshi Biosciences
– KE LIU, M.D., PH.D.: Chief Development Officer, Marengo Therapeutics
– ROGER LUO, PH.D.: Chief Development Officer, Overland Pharmaceuticals
– PEONY YU, M.D.: Chief Medical Officer, Apollomics Inc.

Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.

Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program.

"Local regulatory knowledge and expertise will accelerate early clinical programs, while a global perspective with a focus on US FDA and NMPA requirements, will support key market approvals. Strategies for an East-West MRCT include:

– Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.

– Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market.

– For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favourable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.

Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China.

The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval

Novotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA and NMPA approval process, avoiding delays and additional costs.

Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
communications@novotech-cro.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

InvesTech Holdings Launches Virsical MetaFM, an Integrated Operations and Management Solution for Corporate Equipment and Facilities

HONG KONG, Nov 11, 2022 – (ACN Newswire) – InvesTech Holdings Limited ("InvesTech Holdings"; together with its subsidiaries, "the Group"; stock code: 1087.HK), a leading integrated smart-IT solutions provider in China, is pleased to announce that Wafer Systems Limited ("Wafer Systems"), a subsidiary of the Group that owns the flagship smart-office software product Virsical, recently launched Virsical MetaFM ("MetaFM"), an integrated operations and management solution for corporate equipment and facilities in commercial real estates and smart buildings. MetaFM outperforms traditional management models and empowers the digital transformation of building operations, maintenance and management.

Developed by Wafer Systems, MetaFM is a smart operations management system which is based on the operation, maintenance and management of equipment and facilities in buildings. With input from business interactions and feedback from clients, Wafer Systems has carried out an iterative programme of upgrades to the system. Serving operational goals in areas including security, environmental cleaning and customer service, the system helps optimise the operation, maintenance and management of facilities throughout the full life cycle of buildings. MetaFM offers comprehensive functions, including modules to handle assets and equipment, service centres, order management, preventive maintenance and management, patrol management, inventory management, supplier management, contract management, energy and data management, safe production and emergency planning. As a newly launched smart facility management platform, MetaFM has appealing characteristics, namely comprehensive functional modules, flexible applications, well-established templates, user-friendly interfaces, and a well-designed overall structure, optimising facility management practices.

As a solution specifically designed for the operations and maintenance of buildings and properties, MetaFM adopts Wafer Systems' original platform structure while permitting development in new directions for building space management. Leveraging its powerful back-end self-configuration function, the system helps building operators to make accurate decisions on project operations, maintenance and management. The system also significantly reduces facility operations and maintenance costs, lowers potential risks relating to equipment operations, increases transparency in facility management, and maximises the efficiency of facility operations and maintenance. MetaFM can be applied in a diverse range of scenarios, providing a comprehensive smart space management solution for commercial properties, campuses and corporate offices.

MetaSpace, as a platform empowered by spatial digital twins, mainly facilitates information technology/operational technology (IT/OT) integration. MetaWork, an application platform specifically designed for enterprise digital administrative tasks, mainly supports enterprise employees and visitors, and serves administrative management functions. MetaView, a platform that features visualisation and analysis tools for enterprise digital data, serves as an enterprise management control panel and interactive screen. MetaSpace, MetaWork and MetaView complement one another in terms of functionality, forming a complete loop to provide high-quality, one-stop services for enterprises.

Mr. Ringo Chan, Chairman of InvesTech Holdings, said: "Equipment and facilities play a notably important role in enterprises' production processes and business operations, making the management of equipment and facilities one of the most important aspects of enterprise management. With immense experience in the smart-office sector and experience of serving numerous Fortune 500 clients, we notice that companies are faced with problems in such areas as asset management, operating costs and procedure management. We therefore hope that our newly launched MetaFM can help enterprises overcome different challenges in the operation, maintenance and management of equipment and facilities. Leveraging the most advanced solutions, we have set a new industry standard for facility management, providing more customers with convenient smart-office space and improving overall operations management standards and work efficiency."

"The Group has successfully launched the Meta series of smart-building management solutions, which can be deployed in a wide range of scenarios, providing powerful, comprehensive solutions that support enterprises in fields including employee health, user experience, collaborative efficiency, low-carbon and energy-saving operations, corporate sustainability, and environmental, social and governance (ESG) practices. Further, the Group has developed close strategic partnerships with ecosystem partners in the industry, which are leading cloud service and network providers such as Microsoft, Lark, Huawei and Cisco. Looking ahead, leveraging our strong product ecosystem alongside our research and development capabilities, we will continue to develop and optimise solutions to offer our customers one-stop smart-space solutions and facilitate enterprises' digital transformation," Mr. Chan said.

About InvesTech Holdings Limited
InvesTech Holdings Limited (stock code: 1087.HK) was listed on the main board of the Hong Kong Stock Exchange in 2010. As a leading integrated smart IT solutions provider with more than 30 years of experience in the IT industry, the Group is engaged principally in IT infrastructure systems integration and the smart-office software solutions businesses. The Group has a strong presence in China, with more than 10 offices nationwide and a research and development centre in Xi'an.

Website: http://www.investech-holdings.com/


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Pertamina turns to nature-based solutions to balance climate, energy

JAKARTA, Nov 11, 2022 – (ACN Newswire) – State-owned energy company PT Pertamina has prepared some strategies to balance climate resilience and energy security, which include the development of nature-based solutions.


Pavilion Indonesia at COP27 UNFCCC, Sharm El Sheikh, Egypt (7/11/2022) (ANTARA FOTO/Saptono/aww)


Senior Vice President of Research Technology and Innovation at Pertamina Oki Muraza conveyed this information during a discussion at the Indonesian Pavilion on the sidelines of COP27 in Sharm el-Sheikh, Egypt, on Wednesday (November 9, 2022).

During the discussion, Muraza said that Pertamina has declared its commitment to achieving net-zero emissions by 2060, and the commitment is in line with the emission reduction policy promoted by the Indonesian government.

As part of the commitment, Pertamina is implementing two main strategies: decarbonizing all of its current businesses and building new businesses based on green and sustainable principles.

The decarbonization measures taken by the company have included pushing energy efficiency, zero-flare oil and gas activities, and carbon capture and utilization.

"Some other measures include increasing green electricity in Indonesia, building the electric vehicle ecosystem, and developing nature-based solutions," Muraza added.

He further explained that the nature-based solution policy itself is not something new to Pertamina. However, synergy is needed between nature-based solutions and the energy sector, and both should go hand-in-hand.

Nature-based solutions involve short- and medium-term policies that can support the acceleration of climate technology implementation, which is a long-term policy.

According to Pertamina, those solutions need to be considered while designing carbon mitigation strategies.

"So, we have to not only be able to capture carbon dioxide with natural plants, but also produce something… including rubber and renewable hydrocarbon products. In the end, we expect to have other products from nature-based solutions," Muraza said.

He highlighted three pillars that need to be considered in the development of nature-based solutions for realizing business resilience amid the challenges posed by climate change. The three pillars are community involvement, biodiversity and conservation, and sustainable economy.

In line with these, some vegetations that have potential as nature-based solutions, such as Calophyllum inophyllum and Pongamia pinnata, have been developed since they are beneficial for biofuel development.

In addition, the company believes that the development of the mangrove ecosystem can also be a nature-based solution because it could help absorb 264 tons of CO2 per hectare.

"We have conducted several studies with universities and government institutions on how to promote crops that can provide raw material stocks for green refineries," Muraza said.

He also outlined several initiatives, for instance, capturing methane gas, which can be used for power generation and other purposes, for example, as compressed natural gas.

In addition, the energy company is also developing other initiatives, including processing liquid waste into biomethane and solid biomass waste into ethanol.

Some more initiatives undertaken by Pertamina are the establishment of Carbon Capture and Storage (CCS) centers on the islands of Java, Sumatra, and Kalimantan as well as the development of geothermal utilization in Indonesia.

Contact: Brahmantya Satyamurti Poerwadi, Corporate Secretary, PT Pertamina (Persero)
Email: pcc135@pertamina.com, URL: https://www.pertamina.com
Written by: Yuni Arisandy Sinaga, Editor: Fardah Assegaf (c) ANTARA 2022

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

TJI Announces FY2023 Interim Results, Revenue Up 6.8% to HK$1,261.7 million despite Market Headwinds

HONG KONG, Nov 11, 2022 – (ACN Newswire) – Tam Jai International Co. Limited ("TJI" or the "Company", and together with its subsidiaries, the "Group"; HKEX stock code: 2217), a leading and renowned mixian-specialised fast-casual restaurant chain, today announced its interim results for the six months ended 30 September 2022 ("1H2023" or the "Period"). Revenue of the Group recorded a stable growth of 6.8% to HK$1,261.7 million despite the strong headwinds brought about by COVID-19-related restrictions and a weaker global economy.

Highlights
Assuring results in 1H2023
— Revenue of the Group recorded a stable growth of 6.8% to HK$1,261.7 million despite the strong headwinds brought about by COVID-19-related restrictions and a weaker global economy.
— Operating profit of restaurant operations recorded HK$215.5 million, with the operating profit margin at 17.1%.
— Profit for the Period was HK$82.8 million. Hong Kong business maintained a steady profit margin, while revenue of Mainland China and overseas markets were increasing. Operating profit margin is expected to stabilise in 2H2023 with the gradual recovery quarter from quarter by maintaining high operational efficiency.

Development remained on-track
— As at 30 September 2022, there were 208 self-owned restaurants in operation across Hong Kong, Mainland China, Singapore, and Japan, a net increase of 51 restaurants as compared to 30 September 2021.
— The restaurant network expansion has been on track, and the Group is well-equipped with the infrastructure and talents to execute the development plan in accordance with the listing mandate.
— In 2H2023, the growth momentum is expected to continue. The Group keeps long-term growth in mind while remaining prudent to keep its business profitable and winning through stability.

The increase in revenue was mainly driven by the Group's restaurant network expansion, with Hong Kong being the main revenue contributor. Profit for the Period was HK$82.8 million (1H2022: HK$137.9 million). Basic earnings per share were HK6.2 cents in 1H2023 (1H2022: HK13.8 cents).

Steady Hong Kong Business in Challenging Times
The 5th wave of the COVID-19 pandemic had a lingering effect in Hong Kong during the Period. Together with the adverse market sentiment due to the global and local economic downturn, the overall consumption sentiment had deteriorated, which had hindered the recovery pace of the overall retail consumption and food and beverage (F&B) industry in Hong Kong. This softened the Group's same-store revenue. However, with the gradual recovery quarter from quarter, the Group maintained a steady pace of growth in opening new restaurants, and its revenue target has been met. Hong Kong business continued to deliver a stable profit despite the pressure of global inflation.

Bumpy Overseas and Mainland China Markets Development
Despite the solid growth of the Group's Singapore business, negative growth was recorded in the Mainland China and overseas markets. The business in Mainland China, in respect of which high growth potential was expected, was heavily restrained by COVID-19 related policies, such as cities or district lockdowns and the policies of daily mandatory PCR tests that had affected the Group's performance. In Japan, the Group incurred extra market entry expenses due to the delay of the opening of 2 restaurants, and the business was hit by the surge of COVID-19 cases during the second quarter. The Group has adjusted down its pace of development in Mainland China and Japan while maintaining the momentum of growth for long term. The Group has high hopes on potential in Mainland China and overseas markets, with the infrastructure and foundation established, including branding and marketing, talent recruitment, and staff training, the Group is well equipped for the growth in future.

Cautious and Strategic Development
The Group has been expanding its restaurant network with caution and clearly defined strategic goals, aiming to achieve long-term growth while keeping its business profitable.

During 1H2023, the Group opened 19 new restaurants in Hong Kong, 9 in Mainland China, 5 in Singapore, and 2 in Japan, respectively, bringing the total number of restaurants to 208 as at 30 September 2022, meeting the restaurant network expansion targets in Hong Kong.

Maintaining High Cost-efficiency and Productivity
The Group was able to largely mitigate the impact of the recent wave of inflation with flexibility and innovation by implementing various measures, including direct sourcing and ingredients adaptations, partnering with selected original equipment manufacturer ("OEM") suppliers, and sourcing ingredients substitution of same or better quality and at a lower cost. These measures helped minimise logistics hiccups and costs and mitigated the risk of supply chain disruption.

Meanwhile, the Group managed to maintain a stable staff cost percentage while maintaining restaurant number growth and a higher number of sick days with employees contracted COVID-19. The pressure was lightened through the Group's smart rostering system, which improves cost efficiency in staff management.

Prospects
Ever since the start of the pandemic, TJI has been dedicating itself to the optimisation of its business processes, cost controls, and supply chain management while pushing forward its commitment to restaurant network expansion. Despite all the challenges arising from the pandemic and global economic downturn, the Group is well-positioned for steady growth and recovery through agile management, prudent restaurant network expansion, and impactful brand-building.

In Hong Kong, the Group's profit margin is expected to stabilise with the implementation of various cost-control measures and the improvement of restaurant-level operation. Sales has picked up quarter-on-quarter during the Period, and the growth momentum is expected to continue well into 2H2023, along with the gradual easing of social distancing policies.

The Group's encouraging performance in Singapore during the Period has demonstrated the viability of its operation model in the overseas markets. With the infrastructure and foundation that the Group has established, including branding and marketing, talent recruitment, and staff training, it is highly optimistic about the potential in Mainland China and overseas markets and anticipates resilient growth in the future when the markets recover.

Mr. Daren Lau, Chairman and Chief Executive Officer of TJI, said, "We have persisted through the severe test on the resilience of our business, and yet grasped the opportunities that can maximise our potential for success. Looking forward, we believe that all the adversities shall pass, and the solid foundations we have laid shall elevate us to new height."

About Tam Jai International Co. Limited (HKEX: 2217)
TJI has been listed on The Stock Exchange of Hong Kong Limited (stock code: 02217.HK) since October 2021. It is one of the largest and most popular fast casual resturant chains and the No.1 Asian noodle specialty restaurant operator in Hong Kong.* It primarily operates the TamJai Yunnan Mixian and TamJai SamGor Mixian
brands, with operations in Hong Kong, Mainland China, Singapore and Japan. As at 30 September 2022, the Group operated a total of 208 restaurants. With the first TamJai Yunnan Mixian restaurant and the first TamJai SamGor Mixian restaurant opened in 1996 and 2008 in Hong Kong respectively, it has pioneered and popularised the new mixian trend in Hong Kong.

*In terms of both revenue and number of restaurants in 2020, according to Euromonitor


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Trintech Celebrates the 10-Year Anniversary of Cadency(R) by Trintech

DALLAS, TX, Nov 11, 2022 – (ACN Newswire) – "The Avengers(TM)" came together in 2012 and have defeated numerous villains over the last 10 years. Similarly, Trintech's finance and technology experts also came together in 2012 to launch Cadency(R) – the world's first end-to-end Record to Report SaaS solution transforming the way enterprise finance and accounting professionals around the world close their books. Since then, Trintech has been laser-focused on continuing to help the Superheroes of Finance and Accounting defeat manual work by standardizing, streamlining, and automating their financial close processes.

"The Office of the CFO has evolved considerably over the last ten years, with CFOs serving as key superheroes within their organizations. Today, we celebrate the 10-year anniversary of Cadency and the role it has played in helping global organizations vanquish compliance headaches, rescue un-reconciled balance sheets, and bring peace to the world of transaction matching," said Teresa Mackintosh, CEO of Trintech. "The last three years have asked even more from the Office of Finance, as the pandemic introduced new challenges and increased expectations to conquer. CFOs need to be more agile than ever before and have accurate and accessible data available at any given moment, making solutions like Cadency a must-have in their Superhero toolbelt."

Over the last decade, Cadency(R) has helped organizations around the globe streamline and automate the entire Record to Report process in a standardized control framework. To celebrate the 10-year anniversary of the Cadency launch and the release of Cadency 10.3 this week, Trintech has put together a look at how the heroes of Marvel and the heroes of Finance and Accounting have tallied up some impressive stats over the last ten years:

– Following the successful roll-out of Cadency, Serco now has a centralized global solution that provides greater insight into the total number of reconciliations performed as well as their timeliness and accuracy. Today, Serco is running 5,000 balance sheet reconciliations through Cadency on a monthly basis. In addition, they are auto-reconciling 15,000 accounts which has saved their team a total of 500 hours per month. That's enough time to watch the entire Marvel Cinematic Universe (3,831 minutes of film) over the course of eight months!

– Over 10,000 crew members are listed in the credits of Avengers: Infinity War(TM). That's a huge number, but did you know that Boston Scientific Corporation currently has 29,000+ accounts housed within Cadency, with more than 4,400 of those accounts set to auto-reconcile each month? Additionally, BSC has experienced increased productivity and time savings, greater visibility and standardization across their balance sheet reconciliation and previously manual Journal Entry processes. The automation features inside Cadency have increased their efficiency, as well in areas such as SOX sampling and testing.

– As the Avengers showed us, the best teams need to grow. While they started as a group of six superheroes in 2012, it took over 30 heroes to take down Thanos in Avengers: Endgame(TM). LKQ Corporation, a leading global distributor of vehicle parts and accessories, implemented Trintech's Cadency solution and successfully conducted 130 acquisitions from 2003-2019, growing 38 times their original size with no additional headcount increase to their F&A team. In addition, they were able to reduce their close to six and a half business days, reduce their cash specialist headcount by nearly 50%, and achieve nearly 90% auto-reconciliation.

Looking to become the Superhero of your organization? Learn how Trintech can help. https://www.trintech.com/schedule-demo/

About Trintech

Trintech Inc., a pioneer of financial corporate performance management software, combines technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance – Trintech's portfolio of financial solutions, including Cadency(R), Adra(R), and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Trintech's excellence in both innovation and client support have been recognized with a variety of awards over the years including most recently "Easiest to Do Business With" and "Fastest Implementation" in G2's Fall 2022 Report. Over 3,500 clients worldwide – including the majority of the Fortune 100 – rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.

Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands, and the Nordic countries, as well as strategic partners in South Africa, Latin America, and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter.

Media Contact:
Kelli Shoevlin
Sr. Manager, Global Corporate Marketing & Communications
kelli.shoevlin@trintech.com

SOURCE: Trintech, Inc.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Euromonitor Announces Roborock’s Success in High-end Robot Vacuum Market

SINGAPORE, Nov 10, 2022 – (ACN Newswire) – Recently, Joan Hu, Overseas Southeast Asia Director of Roborock, has announced Roborock’s great success based on Euromonitor data and shared its strategies.

According to data recently released by Euromonitor, worldwide retail sales of robot vacuums exceeded 15 million units in 2021, representing a compound annual growth rate in excess of 20% over the past five years. In particular, the Asia-Pacific region accounted for some 44.2% of the total, making it the world’s largest robot vacuum market. High-end robot vacuums, generally priced at over US$500, deliver far superior performance in terms of intelligence and cleaning efficiency when compared with standard models.

After Roborock announcing its expansion to the Southeast Asia market only in 2020, the company gains its quick success in just two years.

“We truly pride ourselves on our ability to provide consumers with cutting edge technology when it comes to robot vacuums. Users are spoilt for choice when it comes to innovations for smartphone and smartphone-related gadgets. However, there isn’t much growth in the home improvement space. Thus, we saw an opportunity for Roborock to tap into this space and provide technology that aims to provide true convenience to users. In fact, in the first half of 2022, Roborock’s R&D expenses grew 13.74% YoY to 226 million yuan (approx. US$31.6 million)”, said Joan Hu.

How Roborock managed to dominate the High-End robot vacuum market in such a short time, especially with the challenges posed by the pandemic in the past two years? Given the ongoing pursuit of a high-quality household environment, especially in a fast-paced world, there is a growing trend whereby consumers prefer to use robots to do the housework so that they can spend more time on the things that matter or with the people they love. This was prevalent during the pandemic in the past two years as majority of the population across the world had to be stuck at home due to movement restrictions. With a large number of people working from home, household chores’ responsibilities – such as cleaning – become unclear, and caused tension among couples and families living together. Roborock took the lead in increasing exposure and gaining acceptance of robot vacuums among the general public by providing customers with innovative premium products that use cutting-edge technologies to create a cleaner household environment while delivering a hands-free cleaning experience – something that required very little manual interaction from their consumersBy doing so, the leading robot vacuum company has contributed to the growth of the sector.

The strategies of Roborock

Roborock tied up with China’s top online shopping platforms Tmall.com and JD.com, to launch the Super Brand Day campaign. Similarly for their key SEA markets, including Malaysia, Singapore and Thailand, they worked closely with renowned shopping platforms Shopee ands Lazada in a move to raise the awareness of their popular, high-tech products to a wider range of consumer groups, with the aim of enhancing the quality of day-to-day life and well-being of consumers worldwide. It is also through this platform that they were able to exercise credibility of their brand and the services they offer.

On top of that, Roborock also bolstered marketing efforts across the SEA markets – creating localized marketing campaigns in terms of digital and influencer outreach for each market in order to expand their reach to the correct target audience.

How does Roborock’s High-End products differs from its competitors

In March 2022, Roborock rolled out the G10S and S7 MaxV high-end robot vacuums series with the upgraded algorithm system RR mason 9.0, enabling more precise obstacle avoidance and route planning. The series also features the industry’s first VibraRise® sonic vibration technology that scrubs floors up to 3,000 times per minute as well as disruptive integration of Auto Mop Washing, Auto Antibacterial, Auto Tank Refilling, Auto Dust Collection and Auto-Empty Dock, in addition to optional water and drying components. With these technologies, the series has significantly enhanced cleaning efficiency, delivering an optimized hands-free floor cleaning experience.

To further enhance the consumer experience, Roborock also partners with industry leaders, such as INEOS Styrolution. In May this year, they partnered with the company to incorporate Novodur®, INEOS Styrolution’s brand of specialty acrylonitrile butadiene styrene (ABS) copolymers. This allows us to produce robot vacuums in terms of sweeping and mopping, as well as smart cordless dual scrubber to provide consumers with an elevated cleaning experience.

What are Roborock’s aspirations and goals for the local market

Besides growing their online presence, Roborock hope to be able to provide a service centre to better serve existing customers. In the near future, Roborock aims to have their own brand flagship store that will also act as an after-sales service center to provide their consumers with a more wholesome shopping experience.

In the meantime, consumers can look forwards to sales events that Roborock organizes hand-in-hand with their local shopping partners.

About Roborock

Roborock devote into the research, development and production of home cleaning robots and other cleaning appliances. With a vision to help people enjoy the convenience and ease in life, our engineers, designers and manufacturing experts collaborate closely through constant exploration on creating truly functional and durable technological products.

Social Links
Twitter: https://twitter.com/roborockglobal
YouTube: https://www.youtube.com/channel/UC86CMysBnOMlRdBJEfihcUQ
Facebook: https://www.facebook.com/RoborockGlobal
Instagram: https://www.instagram.com/roborockglobal/

Media Contact
Contact: Media team, Roborock
Email: sales@roborock.com
Website: https://global.roborock.com/

SOURCE: Roborock



Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON AND HONG KONG, Nov 10, 2022 – (ACN Newswire) – Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022.

Third Quarter 2022 and Recent Highlights:

— Reported third quarter 2022 revenue of US$80 million
— Reported loss from operations of US$9 million, adjusted earnings1 of US$21 million and adjusted EBITDA2 of US$27 million in the third quarter
— Achieved gross margin of 59% in the third quarter
— Appointed Professor Robert Harris, founder and former CEO of Lakeside Healthcare Group, one of UK's largest GP practices, as Executive Chairman of Prenetics EMEA
— Ended the third quarter with cash and other short-term assets3 of approximately US$250 million
— Obtained HSBC banking facilities of US$50 million for general corporate purposes and liquidity for potential acquisitions, demonstrating confidence from financial institutions

Danny Yeung, Chief Executive Officer and Co-founder of Prenetics, said "I'm very proud of our strong results, demonstrating our continued growth, and reflecting the success we've had in performing over 26 million COVID-19 laboratory and at-home tests to date. Looking ahead, we expect to see continued demand in COVID testing to drive near term revenues. I'm also very excited to see our global clinical strategy taking shape, as we launch more tests into more clinics. As part of our UK restructuring, we've recently added Professor Robert Harris as our Executive Chairman for Prenetics EMEA. We are thrilled to be able to leverage his knowledge and experience as a co-founder and former CEO of Lakeside Healthcare Group, which he grew into one of the largest GP practices in the UK. We believe with the addition of Prof. Harris and our new UK strategy, we aim to provide clinical care to 1 million people by 2025. Lastly, we are now in final discussions for multiple acquisitions in the area of clinical cancer genomics, virtual care and primary care clinics which we believe would be highly synergistic and accretive to Prenetics as we continue on our mission to build an end to end health ecosystem. I look forward to providing key updates in the coming months.

Professor Robert Harris, Executive Chairman of Prenetics EMEA, added "I am thrilled to join Prenetics as they continue to scale the business and approach exciting roll-up opportunities. Having previously built one of the UK's largest GP practices, managing hundreds and thousands of patients, I'm impressed by Prenetics' suite of preventive and diagnostic tests, and their goal of providing a greater level of care to patients."

Financial Guidance

Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.

For full year 2022, Prenetics raises revenue guidance to the range of US$270 million to US$280 million and raises full year adjusted EBITDA guidance to the range of US$47 million to US$53 million.

About Prenetics

Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars – Prevention, Diagnostics and Personalized Care – comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening; and provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. To learn more about Prenetics, visit www.prenetics.com.

Enquires:

Investors:
investors@prenetics.com

Forward-Looking Statements
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions and on information currently available to Prenetics, and also contains certain financial forecasts and projections.

All statements other than statements of historical fact contained in this document, including, but not limited to, statements about Prenetics' future results of operations and financial position, plans for new product development and geographic expansion, objectives of management for future operations, projections of market opportunity and revenue growth, competitive position, and technological and market trends, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "target," "seek" or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Prenetics, which involve inherent risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this document, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. A number of risks and uncertainties could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: changes in applicable laws or regulations applicable to Prenetics; developments related to the COVID-19 pandemic; the regulatory environment and changes in laws, regulations or policies in which Prenetics operate; Prenetics' ability to successfully compete in highly competitive industries and markets; Prenetics' ability to continue to adjust its offerings to meet market demand; Prenetics' ability to attract customers to choose its products and services and grow its ecosystem; political instability in the jurisdictions in which Prenetics operates; the overall economic environment and general market and economic conditions in the jurisdiction in which Prenetics operates; and Prenetics' ability to execute its strategies, manage growth and maintain its corporate culture as it grows. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties included in Prenetics' filings with the U.S. Securities and Exchange Commission (the "SEC") from time to time.

Forward-looking statements speak only as of the date they are made. Prenetics does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required under applicable law.

Website

Prenetics intends to use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company's website at https://www.prenetics.com/. Accordingly, we recommend you to monitor the investor relations portion of our website at https://ir.prenetics.com/ in addition to following our press releases, SEC filings, and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the "Request Email Alerts" section of our investor relations page at https://ir.prenetics.com/. However, the additional information contained on our website is not part of our SEC filings.

Basis of Presentation

Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures." Unaudited Financial Information and Non-IFRS Financial Measures

To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA, adjusted gross profit and adjusted profit for the period. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

Management is excluding from some or all of its non-IFRS operating results (1) Equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, and (4) other discretionary items determined by management. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of (Loss)/Profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)", "Reconciliation of Gross Profit under IFRS and Adjusted Gross Profit (Non-IFRS)" and "Reconciliation of Loss attributable to equity shareholders of Prenetics under IFRS and Adjusted Profit for the period (Non-IFRS)" set forth at the end of this document.

Notes
1. Adjusted Profit (non-IFRS) represents (loss)/profit from operations under IFRS before equity-settled share-based payment expenses, other strategic financing, restructuring costs in relation to UK and diagnostic business, transactional expense and non-recurring expense and fair value adjustments. See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of Loss attributable to equity shareholders of Prenetics under IFRS and Adjusted profit for the period (Non-IFRS)" for more details.
2. Adjusted EBITDA (non-IFRS) represents (loss)/profit from operations under IFRS before equity-settled share-based payment expenses, depreciation and amortization, other strategic financing, restructuring costs in relation to UK and diagnostic business, transactional expense and non-recurring expense, and finance income, exchange gain or loss. See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of (Loss)/Profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)" for more details.
3. Represents current assets, comprising cash and cash equivalents, short-term financial assets, trade receivables, deposits, prepayments and other receivables, deferred expenses and inventory.


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair

HONG KONG, Nov 10, 2022 – (ACN Newswire) – Global healthcare collaboration and innovation are key themes of the Hong Kong Trade Development Council (HKTDC)'s inaugural International Healthcare Week, currently taking place at the Hong Kong Convention and Exhibition Centre (HKCEC). The week is comprised of two anchor events: the second Asia Summit on Global Health (ASGH), co-organised with the Government of the Hong Kong Special Administrative Region (HKSAR) and the 13th Hong Kong International Medical and Healthcare Fair.


The second Asia Summit on Global Health, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC, runs under the theme "Charting a New Course in Healthcare through Collaboration" today and tomorrow.

Dr Zsuzsanna Jakab, Deputy Director-General of the World Health Organization

Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China


The two-day summit kicks off today in hybrid format under the theme of "Charting a New Course in Healthcare through Collaboration", with the second day going online. The 13th International Medical and Healthcare Fair from 9 to 11 November features more than 300 exhibitors showcasing their latest products and developments and brings together industry professionals, institutions and the research and development community. The two concurrent events are catered towards both the upstream and downstream healthcare industries and together create synergies and opportunities for medical and healthcare industry professionals as well as businesses and investors.

As healthcare and the life sciences grow in importance globally, ASGH has brought together more than 80 speakers, including global business leaders and healthcare investors, science and medical experts, healthcare officials, financial specialists and professional service providers to discuss the latest trends and developments in the healthcare and medical fields. Topics covered include business opportunities and challenges for the global healthcare industry, Asia's transformational landscape in healthcare, Hong Kong's strengths in innovation and fundraising for global health as well as how the city facilitates global collaboration through partnerships to tap the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) and beyond.

John Lee, Hong Kong SAR (HKSAR) Chief Executive, spoke at the summit's opening ceremony this morning, along with Margaret Fong, Executive Director of the HKTDC, Zsuzsanna Jakab, Deputy Director-General of World Health Organization (WHO); and Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China. In her welcome remarks, Margaret Fong said: "The pandemic catalysed collaboration. We need to continue this momentum to pave the way to new prospects. These prospects can be found in Asia, the world's fastest-growing healthcare market. Hong Kong as a global financial, business and investment hub and gateway to Mainland China and Asia markets is the ideal base for international companies to seize new opportunities. It is the place to do business and the perfect location for International Healthcare Week."

Addressing ASGH participants at the opening session, John Lee said: "Since taking office in July, my team and I have made substantive progress in lifting restrictions, while containing the number of confirmed cases and protecting the healthcare system and our high-risk population. We are working on specific and dedicated plans to ensure major events and economic activities can be held smoothly, to open up Hong Kong – to bring a world of business back to Hong Kong – as quickly, and as safely, as we can. This Summit, as well as last week's Global Financial Leaders' Investment Summit and Fintech Week, are welcome examples."

Zsuzsanna Jakab added: "As COVID-19 has made clear, health, people's lives and the broader well-being of society are inextricably linked. Yet, COVID-19 has also exposed glaring global inequities. We have an opportunity, indeed an obligation, to learn from this pandemic and accelerate progress towards ensuring that more people benefit from universal health coverage, are protected from health emergencies and enjoy better health and well-being. The WHO will help countries connect and collaborate so that they can work as one team. We will make the greatest impact by working together."

Cao Xuetao stated: "The National Health Commission will be actively supporting Hong Kong in three key areas: persevering in its control of the pandemic; strengthening Hong Kong's medical exchange and integration with the rest of the country; and giving full play to Hong Kong's healthcare talent and resources, which would allow it to participate in important national initiatives and make greater contributions to the work involved in connecting the country to the world and achieving the health goals of the UN's 2030 Agenda for Sustainable Development."

Industry leaders share insights on latest healthcare and medical developments

To address the global impact of the COVID-19 pandemic and help prepare for future healthcare, economic and environmental challenges, this morning's ASGH plenary session "Charting a New Course in Healthcare through Collaboration" invited heavyweight speakers, including Ulrich Betz, Senior Vice President Innovation at Merck; Ruilin Song, Executive President of the China Pharmaceutical Innovation and Research Development Association; Luhan Yang, Co-Founder and CEO of Qihan Biotechnology; and Alex Zhavoronkov, Founder and CEO of Insilico Medicine. They examined the latest trends in the healthcare and medical sectors and the urgent need for global collaboration to strengthen healthcare cooperation for a sustainable future.

A panel discussion titled "The Next Development in China's Healthcare Sector" was held on the first day, with Lo Chung-mau, Secretary for Health of the HKSAR, sharing his views on Hong Kong's role as a strategic conduit connecting Mainland China and the world in the healthcare arena. Additionally, Sun Dong, Secretary for Innovation, Technology and Industry of the HKSAR, delivered special remarks, sharing his valuable insights in a session titled "How Innovation in the Guangdong-Hong Kong-Macao Greater Bay Area Reshapes Global Healthcare". Peter Piot joined the summit and shared his expert perspective on how the world deals with healthcare challenges from Ebola to COVID-19. He is European Union (EU) Chief Scientific Adviser Epidemics and Special Adviser to the European Commission President and former Director and Handa Professor of Global Health of the London School of Hygiene & Tropical Medicine. In addition, the HKTDC and Haitong International published a joint research report on the future of the healthcare industry in Hong Kong and Mainland China.

A plethora of online sessions will be staged tomorrow, covering important topics, such as preparedness for epidemic viruses, health equity, opportunities in the Asia market, the outlook for the biotech industry and medical robotic development. A number of industry leaders and experts have been invited to share their expertise at the summit.

Holistic platform for project owners and potential investors

Following the success of last year's inaugural ASGH, a series of deal-sourcing and matchmaking sessions are taking place to meet the business matching needs of project owners and investors and generate new business opportunities. The exhibition area at ASGH included more than 180 exhibitors, including health innovation and technology companies, research and development institutions, incubation centres and more.

More than 110 start-ups and projects are on view at the InnoHealth Showcase on-site. Live pitching sessions were organised where start-ups presented their innovations in transforming global healthcare and connected with potential investors and business partners for new business opportunities. Private equity and venture capital investors, family offices and high-net-worth individuals joined one-on-one online-to-offline meetings with project owners from around the world through ASGH Deal Flow Matchmaking. The summit also featured the Business of Healthcare Advisory Zone that provides a full range of advisory services to start-ups.

Meanwhile, the 13th International Medical and Healthcare Fair featured the latest medical technologies and devices, healthcare and beauty products and related solutions and services.

Themed zones showcase latest medical products and solutions

The HKTDC Hong Kong International Medical and Healthcare Fair, co-organised with the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), attracted more than 300 exhibitors from Hong Kong and different countries and regions, including seven local universities and pavilions formed by the HKMHDIA, the Hong Kong China Federation of Bodybuilding & Fitness and the Zhejiang Provincial Committee of the China Council for the Promotion of International Trade. The fair is held in hybrid format under the HKTDC's new EXHIBITION+ model. The physical show opened yesterday at the HKCEC and runs until 11 November, while exhibitors and buyers across the world can also connect through the smart business-matching platform Click2Match until 18 November.

Under the theme of "Decoding MedTech Trends", the event features various zones, such as Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Product and World of Health and Wellness, alongside the Startup Zone. Exhibitors presented a wide array of products that highlight the latest medical trends and market demands, such as the ultrasonic Inofab Spiroclinic Pro – IoT Spirometer; the POD Telemedicine Health Checkup Station and a host of other products. Meanwhile, 24 start-up companies are displaying their accomplishments and solutions in the field of medical technology.

The HKMHDIA MedTech Forum 2022 was held yesterday under the theme "Opportunities in the Greater Bay Area". Experts and representatives from the Department of Health of the HKSAR, the Department of Commerce of Guangdong Province, Johnson & Johnson, Konica Minolta and The University of Hong Kong-Shenzhen Hospital, among others, discussed topics, such as market opportunities for medical technologies in the GBA and innovative medical technologies. Industry professionals can watch videos of the events through the fair website ( https://bit.ly/3DNBBXy ). Also, seminars and workshops for industry players are being organised during the fair by the Hong Kong Doctors Union, the Golden Age Foundation and the Hong Kong Science and Technology Parks.

The HKTDC has implemented its new EXHIBITION+ model to run the Hong Kong International Medical and Healthcare Fair. EXHIBITION+ comprises four key exhibition elements, including the physical fair, the smart business-matching platform Click2Match, online-to-offline seminars under the Intelligence Hub and the hktdc.com Sourcing platform, extending face-to-face interactions from physical exhibitions to an online smart business-matching platform to help enterprises connect with business partners proactively.

Websites
– International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en
– Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
– Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
– Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker
– Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en
– Interesting Product List: https://bit.ly/3DOhppL
– Activity Schedule: https://bit.ly/3DehRvF
– Photo download: https://bit.ly/3A20Ow6

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

Media Enquiries

For enquiries please contact:

Asia Summit on Global Health
Yuan Tung Financial Relations:
Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hk
Fung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hk

HKTDC's Communications & Public Affairs Department:
Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.org
Sam Ho, Tel: +852 2584 4569, Email: sam.sy.ho@hktdc.org

Hong Kong International Medical and Healthcare Fair
HKTDC's Communications & Public Affairs Department:
Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Aim to become world-class geothermal electricity producer: Pertamina

JAKARTA, Nov 10, 2022 – (ACN Newswire) – State-owned energy company PT Pertamina is seeking to become a world-class player in green electricity generation based on geothermal energy by pursuing a number of technological innovations to increase geothermal utilization.


PT Pertamina Geothermal Energi (PGE) develops geothermal energy in Ulubelu Area in Tanggamus, Lampung. (ANTARA/HO-PGE)


"We aim to become a world-class player in the geothermal sector. There is an opportunity for that … since, so far, the geothermal potential utilized is still less than 10 percent of the total owned by Indonesia," said Oki Muraza, senior vice president of research technology and innovation at Pertamina.

He made the remarks during a discussion at the Indonesian Pavilion on the sidelines of COP27 in Sharm el-Sheikh, Egypt, on Tuesday (November 8, 2022).

Indonesia has nearly 24 gigawatts (GW) of geothermal potential, but less than 10 percent of it has been utilized, he noted. Therefore, Pertamina sees a great opportunity to further increase the capacity of geothermal utilization in the country to generate green electricity, he added.

Efforts to increase geothermal-based electricity capacity are aimed at supporting Indonesia's target of achieving net-zero emissions by 2060 by increasing the use of renewable energy in the proportion of national electrical energy sources, he said.

For that reason, Pertamina has conducted a lot of research on the development of technological innovations for geothermal utilization, which have covered the fields of exploration, development, production-operation, and digitization.

The state-owned energy company is currently developing better technology in the field of exploration, undertaking a comprehensive study of geoscience, and developing new methods that can be applied in the geothermal industry.

"This is something that we have been doing for years so that we technologically master it, starting from exploration, development, production, drilling, and so on," Muraza said.

Moreover, Pertamina will increase its geothermal capacity, which was recorded at 672 megawatts (MW) in 2020, to 1,128 MW by 2026.

The company is striving to achieve operational excellence in the upstream sector, integrate the development in new areas, and expand the value chain of products from geothermal energy, such as green energy products in the form of green methanol, green hydrogen, nano-silica, green liquid carbon dioxide, and carbon credits.

In addition, Pertamina is also supporting the development of green industrial clusters in the country.

"We hope to accelerate the development of new areas that can be used not only for electricity, but we are also starting to think about possible locations that can be developed for green hydrogen," Muraza informed.

He added that Pertamina is offering cooperation opportunities to players in the field of geothermal and energy efficiency in Indonesia for implementing technological solutions – developed by the company to build more geothermal power plants and other geothermal products – and optimizing the utilization of geothermal potential in the country.

Contact: Brahmantya Satyamurti Poerwadi, Corporate Secretary, PT Pertamina (Persero)
Email: pcc135@pertamina.com, URL: https://www.pertamina.com
Written by: Yuni Arisandy Sinaga, Editor: Suharto (c) ANTARA 2022

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Moonstake Taps Strategic Partner RockX to Integrate SOL Staking

SINGAPORE, Nov 10, 2022 – (ACN Newswire) – Moonstake is pleased to announce we are working with long-time strategic partner RockX to integrate SOL staking. Through this collaborative effort, Moonstake is leveraging RockX Solana validator to bring its users access to the Solana staking ecosystem so they can start earning from staking SOL. Together, Moonstake and RockX will accelerate the growth of Solana in the blockchain industry through staking. Since January 2021, Moonstake has also been working with RockX to support the Polkadot staking ecosystem. Today, Moonstake is a recognized top 10 staking providers in the world and a Verified Provider of the VPP family of the leading staking data aggregator, Staking Rewards. RockX is also a top 13 staking provider globally and also a Verified Provider of Staking Reward's program.



Moonstake started the staking business last year with the aim to create the largest staking network in Asia. Since then, we have developed the most user-friendly Web Wallet and Mobile Wallet (iOS / Android) with support for over 2000 cryptocurrencies. After a full-scale operation launched in August 2020, Moonstake's total staking assets have grown rapidly to reach $1 Billion. After Cosmos, IRISnet, Ontology, Harmony, Tezos, Cardano, Qtum, Polkadot, Quras, Centrality, Orbs (on Ethereum and Polygon), IOST, TRON, Shiden, FIO, EVER, and ROSE, the highly demanded SOL will become the 18th staking coin available on Moonstake.

RockX is a digital assets platform that offers risk-adjusted crypto investment for the masses and allows users to compound their crypto holdings through mining, staking, and other DeFi products. It is currently a leading node operator for popular blockchains like Polkadot, Solana, and Avalanche. Recently, RockX sponsored the global hackathon Solana Summer Camp through the explorer SolanaFM to enable developers of every level to get a headstart in the Web 3.0 space by developing with one of the world's biggest blockchain, Solana. This event successfully took place from July to August 2022 and had up to 5 million USD in global prizes and seed funding.

Solana is a layer-1 blockchain that focuses on scalability, speed, cost minimization, and energy-efficiency. It uses a hybrid model of Proof of Stake (PoS) that combines a unique timestamp-based Proof of History (PoH) algorithm with a high-speed synchronization system. This lets Solana provide a high speed and low-cost experience to both users and developers, promising less than 0.01 USD for transaction fee and 0.001 seconds in transaction time. Thanks to these innovations, Solana has become one of the most popular blockchains for DApp developers and staking users. In fact, the SOL coin now sits in the ranking of the top 10 cryptocurrencies in terms of market capitalization.

Mitsuru Tezuka, Founder at Moonstake says: "We are very pleased to once again work together with partner RockX, one of Solana's world leading node operators. Soon, users of Moonstake can access staking of SOL using RockX's validator, just like before for DOT staking. By combining the market leading platforms of Moonstake and RockX, we are confident that we can support the ever-growing Solana ecosystem together, just like what we have been doing for the Polkadot ecosystem."

Zhuling Chen, CEO at RockX says: "We are pleased to be partnering with Moonstake who is a top-10 staking provider and a user-friendly wallet. I am very happy to be extending our partnership from Polkadot to Solana. Moonstake and RockX will continue to push the boundaries together to improve access to blockchain services and focus further on the growth of our Solana ecosystem, just as we did before with Polkadot."

Follow us on Twitter (https://twitter.com/moonstake) and Telegram (https://t.me/Moonstake_wallet) for the latest updates on Moonstake news!

About Moonstake

Moonstake is the world's leading staking service provider that develops and operates decentralized wallet services for businesses and individuals. Since its launch in April 2020, Moonstake has partnered with 27 leading platform providers, including Cardano's constituent Emurgo, developer of the Polkadot-connected blockchain Astar Network Stake Technologies, and the TRON Network with over 50 million users. In May 2021, Moonstake further enhanced its corporate credibility by becoming a wholly owned subsidiary of OIO Holdings Limited, a company listed on the Singapore Stock Exchange. Using blockchain technology, Moonstake aims to progress toward a world where anyone can easily make use of highly secure and reliable digital asset management tools. https://www.moonstake.io/

About Moonstake's staking business

For the staking industry, which has grown into a 630-billion dollar market as of September 2021, Moonstake provides a decentralized staking service that does not require user deposits, and supports nodes around the world in addition to its own validator nodes. Moonstake currently supports the staking of 18 blockchains. With a total staking assets of 1.8 billion USD and a global user base, the company ranked third out of more than 10,000 providers worldwide in June of the same year.

About RockX

RockX is a global blockchain node network to staking, data, and security. The team is equipped with a wealth of experience in mining, staking, protocol research, and infrastructure design. In recent years, the company has built access node APIs for popular Layer 1 and 2 protocols for developers and helps companies seamlessly access and interact with blockchains.

With over USD 900 million worth of tokens staked, RockX is one of Asia's leading staking platforms. Focusing on serving institutional and high net-worth clients globally to compound their returns on cryptocurrencies, RockX is always open to collaborating with synergistic partners & innovative Web 3.0 projects, ultimately helping to build the decentralised financial ecosystem. https://www.rockx.com/

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com